Sight Sciences Inc (SGHT) USD0.001
Sight Sciences, Inc. is an ophthalmic medical device company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company’s surgical glaucoma product portfolio features the OMNI surgical system (OMNI), a device that facilitates the performance of both trabeculotomy and canaloplasty with a single device and single corneal incision. Its nonsurgical dry eye product portfolio consists of the TearCare system for ophthalmologists and optometrists. TearCare is a wearable eyelid technology that delivers targeted and adjustable heat to the meibomian glands of the eyelids. The Company has two reportable segments: Surgical Glaucoma and Dry Eye. Its Surgical Glaucoma segment consists of sales of the OMNI surgical system. Its Dry Eye segment includes sales of the TearCare system and related components and accessories. The Company primarily sell both the systems through a direct sales model.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.